EDRN Breast and Ovary Cancer CVC, Study 2: Phase 3 retrospective validation of ovarian cancer early detection markers in serial preclinical samples from the PLCO trial

Abbreviated Name: CVC Study 2

Protocol ID: 372

Lead Investigator: Li, Christopher — Fred Hutchinson Cancer Research Center

Coordinating Investigator:

No coordinating investigator defined.

Involved Investigator Sites:

Biomarker Name: CA125, HE4, MSLN, MMP7

Design: No design specified.

Field(s) of Research: Proteomics

Collaborative Group: Breast and Gynecologic Cancers Research Group

Phased Status: 3

Abstract:

This is a Phase 3 validation study that aims to validate and refine two- and four-marker algorithms using serial preclinical samples from the PLCO trial.

Aims: 1. To validate and refine 2-marker and 4-marker algorithms. 2. In a separate independent validation set (the blinded half of the PLCO serial samples) we will validate the refined 2-marker and 4-marker algorithms.

Analytic Method: ROC curves; logistic regression

Comments:

Biomarkers:

There are currently no biomarkers annotated for this protocol.

Datasets:

No datasets are currently associated with this protocol.